{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:36:42Z","timestamp":1780486602437,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jbspin.2023.105599","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T12:24:17Z","timestamp":1685708657000},"page":"105599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database"],"prefix":"10.1016","volume":"90","author":[{"given":"Claire","family":"Amigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Hubert","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Breuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105599_bib0205","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40618-019-01041-6","article-title":"State of the art in osteoporosis risk assessment and treatment","volume":"42","author":"Liu","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jbspin.2023.105599_bib0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jbspin.2023.105599_bib0215","unstructured":"https\/\/www.iofbonehealth.org\/broken-bones-broken-lives.[accessed 24.11.22]."},{"key":"10.1016\/j.jbspin.2023.105599_bib0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrrheum.2017.218","article-title":"Osteoporosis in 2017: addressing the crisis in the treatment of osteoporosis","volume":"14","author":"Roux","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105599_bib0225","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","article-title":"2018 update of French recommendations on the management of postmenopausal osteoporosis","volume":"85","author":"Briot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105599_bib0230","first-page":"100999","article-title":"The use of bone-modifying agents in multiple myeloma","author":"Hussain","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.jbspin.2023.105599_bib0235","doi-asserted-by":"crossref","first-page":"115907","DOI":"10.1016\/j.bone.2021.115907","article-title":"The use of bisphosphonates to treat skeletal complications in solid tumours","volume":"147","author":"D\u2019Oronzo","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2023.105599_bib0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"86","author":"Briot","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105599_bib0245","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","article-title":"2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"81","author":"Briot","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105599_bib0250","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jbspin.2019.07.005","article-title":"French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies","volume":"86","author":"Bouvard","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105599_bib0255","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jbspin.2023.105599_bib0260","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jbspin.2023.105599_bib0265","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2023.105599_bib0270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oooo.2021.03.006","article-title":"Quality of life in patients affected by medication-related osteonecrosis of the jaws: a systematic review","volume":"132","author":"Bensi","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jbspin.2023.105599_bib0275","doi-asserted-by":"crossref","first-page":"866871","DOI":"10.3389\/froh.2022.866871","article-title":"Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ)","volume":"3","author":"Migliorati","year":"2022","journal-title":"Front Oral Health"},{"key":"10.1016\/j.jbspin.2023.105599_bib0280","unstructured":"R Core team. R: A language and environment for statistical computing 2017. https:\/\/www.R-project.org\/.[accessed 24.11.22]."},{"key":"10.1016\/j.jbspin.2023.105599_bib0285","unstructured":"Dean A, Sullivan K, Soe M. OpenEpi: Open Source Epidemiologic Statistics for Public Health 2013. https:\/\/www.OpenEpi.com. [accessed 24.11.22]."},{"key":"10.1016\/j.jbspin.2023.105599_bib0290","doi-asserted-by":"crossref","first-page":"1017391","DOI":"10.3389\/fphar.2022.1017391","article-title":"Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2023.105599_bib0295","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.joms.2021.12.007","article-title":"Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan","volume":"80","author":"Ishimaru","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jbspin.2023.105599_bib0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2023.105599_bib0305","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jbmr.4472","article-title":"Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis","volume":"37","author":"Everts-Graber","year":"2022","journal-title":"J Bone Miner Res Off"},{"key":"10.1016\/j.jbspin.2023.105599_bib0310","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","article-title":"Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"69","author":"Urade","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jbspin.2023.105599_bib0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2023.105599_bib0320","doi-asserted-by":"crossref","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","article-title":"Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review","volume":"9","author":"Fatoye","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2023.105599_bib0325","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jcpe.12455","article-title":"Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis","volume":"42","author":"Gaudin","year":"2015","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.jbspin.2023.105599_bib0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/odi.14003","article-title":"Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: a systematic review","volume":"29","author":"Martins","year":"2023","journal-title":"Oral Dis"},{"key":"10.1016\/j.jbspin.2023.105599_bib0335","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.sdentj.2022.01.003","article-title":"Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies","volume":"34","author":"AlRowis","year":"2022","journal-title":"Saudi Dent J"},{"key":"10.1016\/j.jbspin.2023.105599_bib0340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jbspin.2023.105599_bib0345","doi-asserted-by":"crossref","first-page":"115412","DOI":"10.1016\/j.bone.2020.115412","article-title":"Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis","volume":"137","author":"Lesclous","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2023.105599_bib0350","unstructured":"https:\/\/sfscmfco.fr\/recommandations-de-bonnes-pratiques\/. [accessed 24.11.22]."},{"key":"10.1016\/j.jbspin.2023.105599_bib0355","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2023.105599_bib0360","first-page":"e23500","article-title":"Medication-related osteonecrosis of the jaw: a literature review and update","volume":"60","author":"Kuroshima","year":"2022","journal-title":"Genes N Y N"},{"key":"10.1016\/j.jbspin.2023.105599_bib0365","doi-asserted-by":"crossref","first-page":"822411","DOI":"10.3389\/froh.2021.822411","article-title":"A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw","volume":"2","author":"Bullock","year":"2021","journal-title":"Front Oral Health"},{"key":"10.1016\/j.jbspin.2023.105599_bib0370","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2023.105599_bib0375","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.jbspin.2023.105599_bib0380","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2023.105599_bib0385","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jbspin.2017.12.013","article-title":"Effects and management of denosumab discontinuation","volume":"85","author":"Chapurlat","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105599_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jbspin.2023.105599_bib0395","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/21556660.2019.1579728","article-title":"Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women","volume":"8","author":"Lewiecki","year":"2019","journal-title":"J Drug Assess"},{"key":"10.1016\/j.jbspin.2023.105599_bib0400","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s40618-018-0898-9","article-title":"Adverse effects of media reports on the treatment of osteoporosis","volume":"41","author":"Cipriani","year":"2018","journal-title":"J Endocrinol Invest"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:29:44Z","timestamp":1761150584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1297319X23000787"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105599","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105599"}}